CRISPR Therapeutics AG Stock News

CRISPR Therapeutics and Vertex Pharmaceuticals are partners in one particular program, and they recently won approval for the gene-editing treatment Casgevy. Beyond Casgevy, Vertex has a billion-dollar portfolio of products; Casgevy marks CRISPR Therapeutics' first product approval.

CRISPR Therapeutics could ride the wave of its first approval to deliver solid performance over the long run. Despite decent clinical progress, Ocugen remains a high-risk play that has yet to show its long-run potential.

Trading volume spikes in beaten-down stocks often signal a bottom for prices investors can bank on. The problem is that beaten-down stocks are usually in that position for a good reason, so it helps if there is a catalyst for higher share prices in addition to the trading volume.

CRISPR technology, or Clustered Regularly Interspaced Short Palindromic Repeats, is a revolutionary gene-editing tool that allows scientists to make precise modifications to the DNA of living organisms. It's one of the hottest trends in the stock market today, so I've made a list of three of the most profitable CRISPR stocks to consider.

Growth stocks have been driving the market for most of its history, but the trends have only accelerated recently. Investors are willing to slap a higher and higher premium on these growth stocks as long as they can beat earnings and keep their growth figures high.

Artificial intelligence stocks will be the choice of growth-oriented investors for years to come. But if you're a buy-and-hold investor with above-average patience, this is a time to look for undervalued gene editing stocks.

CRISPR Therapeutics AG investors have endured a challenging bear market decline. CRSP's buying momentum has waned as it struggles to stay above the $50 support level. Crispr's pipeline is mainly in the early stages, with Casgevy being the only commercially approved program.

Imagine this: you walk into a hospital for a procedure. You expect a long, traditional surgery with a lengthy recovery.